According to CoinMeta, and as reported by Reuters, Kenvue fell slightly short of Wall Street's expectations in its second-quarter earnings released on Thursday, with the adjusted gross margin dropping from 60.9% to 60.2%. The consumer health company is currently in the midst of a $40 billion acquisition deal with Kimberly-Clark, which is expected to be completed in the fourth quarter of 2026. Kenvue reported an adjusted earnings per share of 31 cents in the second quarter, below analysts' forecast of 32 cents. Quarterly sales grew by 3% to $3.96 billion, but were slightly lower than the expected $3.97 billion. Sales of self-care products increased by 2.2% to $1.59 billion, skin health and beauty products grew by 5.1% to $1.11 billion, and basic health products grew by 2.3% to $1.25 billion. The company expects to incur pre-tax expenses of about $250 million in 2026 due to a restructuring plan aimed at simplifying operations and reducing costs.